ZULTEMRI Trademark

Trademark Overview


On Thursday, September 24, 2020, a trademark application was filed for ZULTEMRI with the United States Patent and Trademark Office. The USPTO has given the ZULTEMRI trademark a serial number of 90207957. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 10, 2024. This trademark is owned by Bristol-Myers Squibb Company. The ZULTEMRI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pha...
zultemri

General Information


Serial Number90207957
Word MarkZULTEMRI
Filing DateThursday, September 24, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 10, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 14, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for use in disease testing
Translation of Words in MarkThe wording "ZULTEMRI" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 4, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Monday, September 28, 2020NEW APPLICATION ENTERED
Wednesday, November 4, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 27, 2021ASSIGNED TO EXAMINER
Monday, February 1, 2021NON-FINAL ACTION WRITTEN
Monday, February 1, 2021NON-FINAL ACTION E-MAILED
Monday, February 1, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 29, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 29, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 30, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 5, 2021EXAMINERS AMENDMENT -WRITTEN
Thursday, August 5, 2021EXAMINERS AMENDMENT E-MAILED
Thursday, August 5, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, August 5, 2021EXAMINER'S AMENDMENT ENTERED
Thursday, August 5, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 14, 2021PUBLISHED FOR OPPOSITION
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 9, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, May 5, 2022SOU TEAS EXTENSION RECEIVED
Thursday, May 5, 2022SOU EXTENSION 1 FILED
Thursday, May 5, 2022SOU EXTENSION 1 GRANTED
Saturday, May 7, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 2, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 2, 2022SOU EXTENSION 2 FILED
Wednesday, November 2, 2022SOU EXTENSION 2 GRANTED
Friday, November 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 26, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, April 26, 2023SOU EXTENSION 3 FILED
Wednesday, April 26, 2023SOU EXTENSION 3 GRANTED
Friday, April 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 12, 2023SOU EXTENSION 4 FILED
Thursday, October 12, 2023SOU EXTENSION 4 GRANTED
Monday, June 10, 2024ABANDONMENT - NO USE STATEMENT FILED
Friday, July 12, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Saturday, October 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 12, 2023SOU TEAS EXTENSION RECEIVED